Browse the corpus

Angiotensin II receptor blockers are a class of medications that selectively inhibit the binding of angiotensin II to the angiotensin type 1 receptor. This inhibition produces vasodilation, decreases aldosterone secretion, and lowers blood pressure. Angiotensin II receptor blockers are commonly prescribed for hypertension, congestive heart failure, and chronic kidney disease, including diabetic nephropathy. Their therapeutic role overlaps with that of angiotensin-converting enzyme inhibitors, but angiotensin II receptor blockers offer a valuable alternative for patients who experience adverse effects, such as cough or angioedema, with angiotensin-converting enzyme inhibitors. Although generally well-tolerated, angiotensin II receptor blockers may lead to hyperkalemia, hypotension, dizziness, or renal impairment. These medications are contraindicated during pregnancy and require caution in patients with bilateral renal artery stenosis. When combined with potassium-sparing diuretics or supplements, the risk of hyperkalemia increases. Their favorable safety and efficacy profiles make angiotensin II receptor blockers an important component of cardiovascular and renal disease management. Through this educational activity, the participant gains a deeper understanding of the pharmacologic properties, therapeutic applications, and safety considerations of Angiotensin II receptor blockers. Mastery of these principles enhances clinical judgment in selecting appropriate treatment strategies for individuals with hypertension and related conditions. The participant also develops greater confidence in recognizing and managing potential drug interactions and adverse reactions. Collaboration within an interprofessional healthcare team comprising physicians, pharmacists, and nurses improves patient monitoring, medication adherence, and outcomes. By integrating multidisciplinary perspectives, the team ensures comprehensive care that aligns therapeutic goals with patient safety, ultimately advancing the quality and effectiveness of treatment for cardiovascular and renal disorders. Objectives: Evaluate patients for suitability for angiotensin II receptor blocker therapy based on clinical indications, contraindications, comorbid conditions, and potential risk factors for adverse effects or drug interactions.

Through this educational activity, the participant gains a deeper understanding of the pharmacologic properties, therapeutic applications, and safety considerations of Angiotensin II receptor blockers. Mastery of these principles enhances clinical judgment in selecting appropriate treatment strategies for individuals with hypertension and related conditions. The participant also develops greater confidence in recognizing and managing potential drug interactions and adverse reactions. Collaboration within an interprofessional healthcare team comprising physicians, pharmacists, and nurses improves patient monitoring, medication adherence, and outcomes. By integrating multidisciplinary perspectives, the team ensures comprehensive care that aligns therapeutic goals with patient safety, ultimately advancing the quality and effectiveness of treatment for cardiovascular and renal disorders. Objectives: Evaluate patients for suitability for angiotensin II receptor blocker therapy based on clinical indications, contraindications, comorbid conditions, and potential risk factors for adverse effects or drug interactions. Select an angiotensin II receptor blocker that best suits the clinical presentation. Improve communication strategies to educate patients taking angiotensin II receptor blockers regarding proper medication use, potential side effects, the importance of adherence, and when to seek medical attention for concerning symptoms. Implement effective collaboration and communication among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from angiotensin II receptor blockers. Access free multiple choice questions on this topic.

A retrospective analysis of 206 monoexposures to ARBs reported to Poisons Information Centres in Austria, Germany, and Switzerland found that most children (82.7%) and over half of adults (53.6%) remained asymptomatic. The median ingested dose was 2.3 times the maximum recommended daily dose, adjusted for body weight, in children and 6.8 times in adults. Only 1 pediatric patient developed hypotension requiring intravenous fluid administration after ingesting 8.75 times the maximum recommended daily dose of candesartan. Medical evaluation is advised only for symptomatic individuals or those who have ingested 5 times or more the recommended maximum dose based on body weight.[40] A literature review on ARB overdose describes a typical presentation of hypotension and shock resulting from vasodilation, marked by a high cardiac index and low systemic vascular resistance. Coingestion with CCBs is frequently reported. Metabolic abnormalities often include normal anion-gap metabolic acidosis and elevated lactate levels, suggesting tissue hypoxia. The shock pattern is vasoplegic rather than cardiogenic, supported by echocardiographic findings of preserved cardiac function. Hypotension tends to have a delayed onset and prolonged duration, consistent with the long half-life of olmesartan (10–15 hours), and may persist for more than 16 hours postingestion. In one case, the patient’s condition remained resistant to conventional therapies typically used for CCB toxicity, including intravenous fluids, calcium gluconate, glucagon, and high-dose insulin euglycemia therapy.[41] Initial treatment in the case report focused on supportive measures, including aggressive fluid resuscitation and airway protection through intubation and mechanical ventilation. The patient remained hypotensive despite these interventions and the use of catecholamines, underscoring the limited benefit of these agents in ARB toxicity due to suppression of the sympathetic nervous system. Diagnostic clues pointing to ARB involvement included the failure of CCB-directed therapies and the persistence of vasodilatory shock.

Initial treatment in the case report focused on supportive measures, including aggressive fluid resuscitation and airway protection through intubation and mechanical ventilation. The patient remained hypotensive despite these interventions and the use of catecholamines, underscoring the limited benefit of these agents in ARB toxicity due to suppression of the sympathetic nervous system. Diagnostic clues pointing to ARB involvement included the failure of CCB-directed therapies and the persistence of vasodilatory shock. Vasopressin, introduced as a 2nd-line vasopressor, effectively raised mean arterial pressure via vasopressin-1a receptor-mediated vasoconstriction. ATII may also be beneficial as a vasopressor in shock related to ARB overdose. The patient responded favorably, with vasopressor support discontinued by day 3 and full recovery achieved without sequelae. Extracorporeal membrane oxygenation remains a potential option for patients with cardiorespiratory failure who deteriorate despite maximal supportive therapy.[42]

Effective hypertension management often requires a comprehensive approach involving physicians, advanced practice providers, nurses, pharmacists, and relevant specialists. Comorbid conditions such as diabetes, heart failure, renal impairment, and obesity frequently coexist with hypertension and warrant collaborative care across multiple specialties. ARB therapy remains a key option for patients with hypertension and concomitant diabetes or heart failure. Initiating treatment early following diagnosis improves outcomes, emphasizing the importance of prompt intervention, particularly as cardiovascular disease increasingly affects younger individuals.[43] Initiating ARB therapy benefits from active pharmacist involvement to verify appropriate dosing, identify potential drug interactions or contraindications, counsel patients, and communicate concerns to the prescriber. Nurses contribute by addressing patient questions, providing instruction on proper administration, and maintaining communication with both the prescriber and the pharmacist. This collaborative approach optimizes patient outcomes. Physicians and advanced practice providers are responsible for initiating, monitoring, and adjusting ARB therapy, while critical care specialists manage overdose cases. In addition to pharmacologic management, physicians should encourage lifestyle modifications such as weight loss, which may reduce systemic inflammation and improve systolic blood pressure.[44] Ongoing communication among clinicians, pharmacists, and nurses is essential to reduce adverse effects and maximize the therapeutic benefit of ARB treatment.